KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Return on Sales (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Return on Sales data on record, last reported at 0.37% in Q4 2025.

  • For Q4 2025, Return on Sales rose 6.0% year-over-year to 0.37%; the TTM value through Dec 2025 reached 0.33%, up 38.0%, while the annual FY2025 figure was 0.33%, 38.0% up from the prior year.
  • Return on Sales reached 0.37% in Q4 2025 per VRTX's latest filing, up from 0.35% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.43% in Q3 2021 and bottomed at 1.36% in Q2 2024.
  • Average Return on Sales over 5 years is 0.26%, with a median of 0.37% recorded in 2022.
  • Peak YoY movement for Return on Sales: plummeted -173bps in 2024, then skyrocketed 171bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 0.37% in 2021, then fell by -4bps to 0.36% in 2022, then grew by 8bps to 0.38% in 2023, then fell by -19bps to 0.31% in 2024, then rose by 19bps to 0.37% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 0.37% in Q4 2025, 0.35% in Q3 2025, and 0.35% in Q2 2025.